OKYO Pharma (NASDAQ:OKYO – Get Free Report) is projected to post its Q4 2026 results after the market closes on Monday, August 10th. Analysts expect OKYO Pharma to announce earnings of ($0.04) per share for the quarter. Interested persons may visit the the company’s upcoming Q4 2026 earning summary page for the latest details on the call scheduled for Monday, July 20, 2026 at 7:00 AM ET.
OKYO Pharma Price Performance
OKYO opened at $1.49 on Friday. The stock has a fifty day moving average of $1.57 and a 200-day moving average of $1.68. OKYO Pharma has a fifty-two week low of $1.34 and a fifty-two week high of $3.35.
Wall Street Analysts Forecast Growth
OKYO has been the topic of several analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of OKYO Pharma in a research report on Friday, July 17th. HC Wainwright lowered their price objective on shares of OKYO Pharma from $7.00 to $5.00 and set a “buy” rating for the company in a research report on Monday, July 13th. Three research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, OKYO Pharma presently has an average rating of “Hold” and an average target price of $5.67.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Citadel Advisors LLC bought a new stake in OKYO Pharma during the third quarter valued at $31,000. Renaissance Technologies LLC raised its position in shares of OKYO Pharma by 235.0% in the 4th quarter. Renaissance Technologies LLC now owns 138,000 shares of the company’s stock worth $286,000 after acquiring an additional 96,800 shares in the last quarter. Finally, XTX Topco Ltd bought a new position in shares of OKYO Pharma in the 4th quarter worth about $36,000. 2.97% of the stock is owned by institutional investors and hedge funds.
About OKYO Pharma
Okyo Pharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for inflammatory and fibrotic diseases. The company’s pipeline is built on proprietary Fc-fusion technology designed to modulate immune responses associated with conditions such as diabetic nephropathy and chronic graft-versus-host disease. Okyo Pharma seeks to address significant unmet medical needs by targeting key cytokine pathways involved in tissue inflammation and fibrosis.
Okyo Pharma’s lead product candidate, OK-101, is an Fc-fusion protein in Phase 2 development for the treatment of diabetic kidney disease.
Featured Stories
- Five stocks we like better than OKYO Pharma
- Quantum Earnings Week: Winners and Losers Are Finally Emerging
- Axon’s Post-Earnings Pullback May Be More About Valuation Than Growth
- Uber Stock Lags in 2026, But Cash Flow and AV Bets Fuel Upside
- AppLovin Stock Hits 52-Week Low as Analysts Trim Targets, Stay Bullish
Receive News & Ratings for OKYO Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OKYO Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
